The Cabinet Committee on Economic Affairs (CCEA) has given its approval for the proposal of Mylan Inc., USA, as recommended by FIPB, to acquire 100% of the fully paid up share capital of Agila Specialities, subsidiary of Strides Arcolab. The approval would result in foreign investment amounting to Rs 5,168 crore approximately in the country.
In February this year, Strides Arcolab inked definitive agreement with Nasdaq listed Mylan Inc for the sale of its specialties subsidiary. As per the pact, Strides along with its subsidiary will receive a consideration of $1,600 million in cash on closing. Further, a potential additional sum of up to $250 million too would be received subject to the satisfaction of certain conditions by the parent company.
Strides Arcolab is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures wide range of IP-lead niche pharmaceutical products with an emphasis on sterile injectables.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: